ATRC vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ATRC has a Piotroski F-Score of 5/9, indicating stable financial health, but lacks an Altman Z-Score for distress risk assessment. The company shows strong revenue growth (15.8% YoY) and impressive earnings surprise trends, yet remains unprofitable with negative margins and ROE. High valuation multiples and insider selling offset bullish analyst sentiment and improving operational trends. The stock trades at a premium to the target, suggesting limited near-term upside despite growth potential.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ATRC vs MRK: Head-to-Head Comparison
This page compares AtriCure, Inc. (ATRC) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.